Vidwan-ID : 404886



  • Dr Abhimanyu Dev

  • Assistant Professor
  • Birla Institute of Technology, Mesra
Publications 2010 - 2022

Publications

  • 20
    Journal Articles
  • 4
    Book Chapter
  • 2
    Conference
    Proceedings
  • 6
    Review
  • 6
    Projects
  • 1
  • 5

Citations / H-Index

151 Citations
6 h-index
55 Citations

Altmetrics

12
1
7
22
14

Google Scholar

Co-author Network


Expertise

Miscellaneous Biology

Dr. Abhimanyu Dev Is Basically A Molecular Biologist and Having A Pharmaceutical Biotechnology Specialization At His Post Graduate Level. During His Master’S Internship In A Reputed Csir Laboratory At Central Drug Research Institute (Cdri), Lucknow, He Worked In The Area of Cloning and Expression of Ribosomal Proteins For Development of Suitable Vaccine In Mycobacterium Tuberculosis. During His Doctoral Research, He Also Worked For Development of Oral Vaccine In Vibrio Cholerae.

Personal Information

Dr Abhimanyu Dev

Male
Department of Pharmaceutical Sciences & Technology Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra
Ranchi, Jharkhand, India - 835215


Experience

  • Assistant Professor

    Department of Pharmaceutical Sciences and Technology

    Birla Institute of Technology, Mesra

  • Lecturer

    Royal College of Pharmacy and Health Sciences

  • Research Scholar

    CSIR-Central Drug Research Institute


Qualification

  • Ph. D

    Birla Institute of Technology, Mesra


Membership In Professional Bodies

Association of Pharmaceutical Teachers in India (APTI)

Life Member

Association of Microbiology of India (AMI)

Life Member

Association of Pharmaceutical Teachers in India (APTI)

Life Member

Association of Microbiology of India (AMI)

Life Member

Read Less

Research Projects

Development of multi-functional nano-HAP bone substitute for effective bone regeneration in critical defects

Funding Agency : DST NanoMission

Aptamer-based Rapid Diagnostic Kit for Detection of Corona Virus Infection (CoVapt)

Funding Agency : DST SERB

Phenyloxazoline Synthetase Inhibitors as Antitubercular Agents (POSIAA)

Funding Agency : DST SERB

Read More

Development of multi-functional nano-HAP bone substitute for effective bone regeneration in critical defects

Funding Agency : DST NanoMission

Aptamer-based Rapid Diagnostic Kit for Detection of Corona Virus Infection (CoVapt)

Funding Agency : DST SERB

Phenyloxazoline Synthetase Inhibitors as Antitubercular Agents (POSIAA)

Funding Agency : DST SERB

Insilico design, synthesis and evaluation of novel azoles as HIV-1-RT inhibitors

Funding Agency : UGC

Formulation and characterization of multiparticulate pulsatile delivery of methotrexate based on chronotherapy for rheumatoid arthritis and it’s in vitro studies

Funding Agency : UGC

Development of dual functionalized carbogenic nanocarrier for active targeting of CD44 and αvβ3 integrin receptors in breast cancer

Funding Agency : ICMR

Read Less

Patents



Read Less